Founded:

Ferring was first founded in Sweden in 1950 by Dr. Frederik Paulsen

Headquarters:    

Saint-Prex, Switzerland

International:

Ferring International Center (Switzerland)

Two International PharmaScience Centres (Denmark and USA)

Production sites in eight countries (Argentina, China, Czech Republic, Denmark, Germany, Israel, Mexico and Switzerland).

Three R&D Centres (Denmark, Israel, USA)

Market presence:

In more than 45 countries

Workforce:    

More than 3700 employees worldwide

2008 sales:

EUR 865 Million

Growth:

Double-digit average annual growth rate over the last two decades

Urology:

MINIRIN (desmopressin)* is the treatment of choice for bedwetting in children and nocturia in adults.

FIRMAGON (degarelix)* is a treatment for advanced hormone-dependent prostate cancer.

TESTIM (testosterone)** is an efficacious and convenient treatment for men suffering from low testosterone.

Reproductive Health:

MENOPUR (Menotropin)* (REPRONEX in the US) and BRAVELLE* (hFSH) are ovarian-stimulating treatments used in preparation for in-vitro fertilisation (IVF).

TRACTOCILE (Atosiban)* is used to treat pre-term (premature) labour.

Endocrinology:

ZOMACTON (Somatropin)* is a recombinant human growth hormone used to treat growth failure in children.

Gastroenterology:

PENTASA (mesalazine)* is used for the treatment of inflammatory bowel diseases.

GLYPRESSIN (terlipressin)* for Bleeding Oesophageal Varices and (in some markets) for Hepatorenal syndrome.